Found in 1989, Synmax is a leading technology company focused on developing cost-effective intermediates for the pharmaceutical market as well as specialty chemicals for the electronics industry. Relying on our synthesis and bioconversion platform, Synmax offers a broad range of products and services.
While maintaining our production of 7-ADCA, an intermediate for the cephalosporin antibiotics, we have developed a new series of intermediates for cardiovascular drugs using bioprocess. Relying on our enzymatic platform we hope for further develop other products as well. On electronics front, we have successfully developed various fine chemicals for Taiwan's TFT-LCD, CD-R and PCB companies. In the future, we hope to further our competence in these two fields.
Over the past decade, Synmax has established strong relationship with our customers in the Bulk and Pharmaceutical fields providing chiral products and others through complex synthesis based on the core values of reliability and flexibility.
Synmax's fundamental objective is to provide our partners with a seamless transition through every stage of the product delivery pipeline. This objective will continue to be fulfilled through the application of our core business strategy, a strategy for growth which embraces our competitive advantages, product discovery and development. Through early stage involvement in product discovery programms, we will corporate our partners in the later stages of product delivery.
Human resources are no longer a variable cost in the financial report, but rather the most important and valuable asset in the organization. To think highly of personnel quality is the main reason that we can innovate constantly. The individual strengths and team corporation result in high-quality products and service. Relying on outstanding R&D personnel, we have competitive product. The motive power to urge employees is to support them rather than control them.
Taiwan,China
